ClinicalTrials.gg
CompletedNCT03759600Updated Jul 16, 2024Results posted

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

A Phase 2 interventional study of Niraparib in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Takeda. Completed at 33 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
31st of 44
20 · median 41
Started
2018
with 4 others
Phase 2
18 of 44
5 open now
Registered
19th of 44
by date
Lead sponsor
2 of 44
Takeda

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 31st largest by enrollment, is one of 5 that started in 2018, is one of 18 in phase 2, and was the 19th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4 previous chemotherapy regimens.

Read the detailed description

The drug being tested in this study is called niraparib. Niraparib is being tested to treat people who have the homologous recombination deficiency (HRD)-positive, advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. This study will look at the efficacy and safety of niraparib in Japanese participants.

The study will enroll approximately 16 participants. Participants will be enrolled to one group and after that will be asked to take niraparib capsules at the same time each day throughout the study:

  • Niraparib 300 mg

This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately 23 months. Participants will make multiple visits to the clinic in the treatment period, and the post-treatment period including follow-up assessments after the last dose of the study drug.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese female participants aged 20 years or older on the day of signing .
  2. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  3. Participants must agree to undergo tumor homologous recombination deficiency/deficient (HRD) testing, and this test result must show that participants have an HRD-positive tumor (defined by the presence of a deleterious or suspected deleterious breast cancer gene (BRCA) mutation or be positive for genomic instability) by the central laboratory selected by the sponsor.

    Note 1: The study HRD test result must be received prior to enrollment. The tumor sample may be submitted for HRD testing prior to the screening period (ie, within 40 days before Cycle 1 Day 1) if the consent has been obtained and it appears the participant is likely to meet other eligibility requirements.

    Note 2: If historic blood germline BRCA mutation (gBRCAmut) is detected by a prior gBRCAmut testing, then tumor HRD sample test results are not required prior to enrollment; however, HRD testing still needs to be performed.

  4. Participants must have diagnosed, , high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and have not experienced disease progression at least 6 months to the last chemotherapy containing platinum-based anticancer agents.
  5. Participants must have completed 3 or 4 previous chemotherapy regimens. Participants must have completed their last chemotherapy regimen >4 weeks prior to treatment initiation.
  6. Participants must have at least one according to (RECIST) (v.1.1).
  7. Participants must have performance status of ≤1 on the (ECOG) Performance Status Scale.
  8. Participants must have adequate organ function as indicated by the following laboratory values:

    • (ANC) ≥1,500/μL.
    • count ≥150,000/μL.
    • ≥10 g/dL.
    • Serum creatinine ≤1.5× institutional (ULN) OR calculated ≥50 mL/minute, using the Cockcroft-Gault equation.
    • Total ≤1.5×ULN OR direct bilirubin ≤1×ULN.
    • (AST) and alanine aminotransferase (ALT) ≤2.5×ULN unless liver were present, in which case they had to be ≤5×ULN.
  9. Participants must have formalin-fixed, paraffin-embedded tumor samples available from the primary or recurrent cancer or agree to undergo fresh prior to study treatment initiation.
  10. Participants must be able to take oral medications.
  11. Female participants of must be negative for pregnancy test (beta-human chorionic gonadotropin [β-hCG]) within 7 days prior to receiving the first dose of study treatment.
  12. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of childbearing potential, agree to practice 1 highly effective method of and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)

Exclusion criteria

Exclusion Criteria

  1. Participants who have had palliative radiotherapy encompassing >20% of the bone marrow within 1 week of the first dose of study treatment.
  2. Participants who have any known, persistent (>4 weeks), Grade ≥3 hematologic toxicity from last cancer therapy.
  3. Participants who have any known, persistent (>4 weeks), Grade ≥3 fatigue during the last cancer therapy.
  4. Participants who have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
  5. Participants who have symptomatic, uncontrolled brain or .

    To be considered "controlled," central nervous system (CNS) disease must have undergone treatment (eg, radiation or chemotherapy) at least 1 month prior to study enrollment. The participant must not have had any new or progressive signs or symptoms related to the CNS disease and must have been taking a stable dose of or no steroids (as long as these were started at least 4 weeks prior to enrollment] or no steroids). A scan to confirm the absence of at baseline was not required. Participants with spinal cord compression might have been considered if they had received definitive treatment for this and evidence of clinically stable disease for 28 days.

  6. Participants who have known to the components of niraparib.
  7. Participants who have had prior treatment with a known poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors.
  8. Participant who have had treatment with any products within 28 days or 5 half-lives (whichever was longer) before the first dose.
  9. Participants who have had major surgery per Investigator judgment within 3 weeks of the first dose. Participant must have recovered from any effects of any major surgery.
  10. Participants who have diagnosis, detection, or treatment of invasive second primary other than ovarian cancer ≤24 months prior to study enrollment (except basal or squamous cell carcinoma of the skin that was definitively treated). Note: Participants must not have any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), irrespective of the time for disease history.
  11. Participants who are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days of the first dose) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, small bowel obstruction or other serious gastrointestinal disorder, or any psychiatric disorder that prohibits obtaining .
  12. Participants who have received a transfusion ( or red blood cells) within 4 weeks of the first dose of study treatment.
  13. Participants who have received a live virus or bacterial vaccines within 4 weeks of the first dose of study treatment.
  14. Participants who have a history or current evidence of any condition, therapy, or lab abnormality (including active or uncontrolled myelosuppression [ie, anemia, leukopenia, neutropenia, thrombocytopenia]) that might confound the results of the study, interfere with the participant's participation throughout the study period, or study participation is not in the best interest of the participant.
  15. Participants who are regular user (including "recreational use") of any illicit drugs at the time of signing informed consent or have a recent history (within the past year) of drug or alcohol abuse.
  16. Participants who are pregnant or breast-feeding or expecting to conceive within the planned duration of the study.

    NOTE: If a breast-feeding woman discontinue breast-feeding, she may be enrolled in the study.

  17. Participants who are (participants with splenectomy are allowed).
  18. Participants who have known (HIV) positive.
  19. Participants who have known surface antigen (HBsAg) positive, or known or suspected active virus (HCV) infection.

NOTE: Participants who are positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antibody (HBsAb) can be enrolled but must have an undetectable hepatitis B virus (HBV) viral load. Participants who have positive hepatitis C virus antibody (HCVAb) must have an undetectable HCV viral load.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Niraparib 300 mg

    Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 to 28 of each 28-day treatment cycle for up to 50 cycles.

    Drug: Niraparib

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants achieving CR or PR as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD.

    Time frame: Until disease progression or death (Up to 3.8 years)

Secondary outcomes

  1. Duration of Response (DOR)

    DOR was defined as the time from the first documented CR or PR per RECIST v.1.1 to disease recurrence or objective disease progression whichever occurs first. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD.

    Time frame: Until disease progression or death (Up to 3.8 years)

  2. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants achieving CR, PR or SD as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline.

    Time frame: Until disease progression or death (Up to 3.8 years)

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)

  4. Number of Participants With Grade 3 or Higher TEAEs

    An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.

    Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)

  5. Number of Participants With Serious TEAEs

    An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)

  6. Number of Participants With TEAEs Leading to Drug Discontinuation

    An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)

  7. Number of Participants With TEAEs Leading to Dose Interruption

    An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)

  8. Number of Participants With TEAEs Leading to Dose Reduction

    An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)

  9. Progression Free Survival (PFS)

    PFS was defined as the time in months from the date of first study drug administration to the date of first documentation of PD or death as assessed by the RECIST v.1.1. Per RECIST 1.1, PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline.

    Time frame: Until disease progression or death (Up to 3.8 years)

  10. Overall Survival (OS)

    OS was defined as the time in months from the study enrollment to death due to any cause.

    Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)

07

Results

Posted Aug 11, 2020

Participant flow

Participants took part in the study at 17 investigative sites in Japan from 26 December 2018 to 28 December 2022.

Participant flow — Overall Study
MilestoneNiraparib 300 mg
Started20
Completed0
Not completed20
Withdrew: Adverse event2
Withdrew: Progressive disease15
Withdrew: Site terminated by sponsor3

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants achieving CR or PR as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD.

Time frame:
Until disease progression or death (Up to 3.8 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsNiraparib 300 mg
Objective Response Rate (ORR)60.0
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first documented CR or PR per RECIST v.1.1 to disease recurrence or objective disease progression whichever occurs first. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD.

Time frame:
Until disease progression or death (Up to 3.8 years)
Reported as:
Median · months
Duration of Response (DOR)
monthsNiraparib 300 mg
Duration of Response (DOR)9.9 (3.9 to NA)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants achieving CR, PR or SD as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline.

Time frame:
Until disease progression or death (Up to 3.8 years)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsNiraparib 300 mg
Disease Control Rate (DCR)90.0 (68.302 to 98.765)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsNiraparib 300 mg
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)20
SecondaryNumber of Participants With Grade 3 or Higher TEAEs

An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.

Time frame:
From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher TEAEs
ParticipantsNiraparib 300 mg
Number of Participants With Grade 3 or Higher TEAEs17
SecondaryNumber of Participants With Serious TEAEs

An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Reported as:
Count of participants · Participants
Number of Participants With Serious TEAEs
ParticipantsNiraparib 300 mg
Number of Participants With Serious TEAEs8
SecondaryNumber of Participants With TEAEs Leading to Drug Discontinuation

An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Drug Discontinuation
ParticipantsNiraparib 300 mg
Number of Participants With TEAEs Leading to Drug Discontinuation2
SecondaryNumber of Participants With TEAEs Leading to Dose Interruption

An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Dose Interruption
ParticipantsNiraparib 300 mg
Number of Participants With TEAEs Leading to Dose Interruption15
SecondaryNumber of Participants With TEAEs Leading to Dose Reduction

An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Dose Reduction
ParticipantsNiraparib 300 mg
Number of Participants With TEAEs Leading to Dose Reduction16
SecondaryProgression Free Survival (PFS)

PFS was defined as the time in months from the date of first study drug administration to the date of first documentation of PD or death as assessed by the RECIST v.1.1. Per RECIST 1.1, PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline.

Time frame:
Until disease progression or death (Up to 3.8 years)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsNiraparib 300 mg
Progression Free Survival (PFS)8.3 (5.6 to 13.8)
SecondaryOverall Survival (OS)

OS was defined as the time in months from the study enrollment to death due to any cause.

Time frame:
From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Reported as:
Median · months
Overall Survival (OS)
monthsNiraparib 300 mg
Overall Survival (OS)24.9 (14.9 to NA)

Adverse events

Collected over From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niraparib 300mg13/20 (65%)8/20 (40%)20/20 (100%)
Most frequent serious events
Most frequent serious events
EventNiraparib 300mg
AnaemiaBlood and lymphatic system disorders2/20
Platelet count decreasedInvestigations2/20
AscitesGastrointestinal disorders1/20
DyspnoeaRespiratory, thoracic and mediastinal disorders1/20
EmbolismVascular disorders1/20
IleusGastrointestinal disorders1/20
Intestinal obstructionGastrointestinal disorders1/20
Parathyroid tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/20
Most frequent other events
Showing 10 of 31
Most frequent other events
EventNiraparib 300mg
AnaemiaBlood and lymphatic system disorders14/20
NauseaGastrointestinal disorders12/20
Platelet count decreasedInvestigations10/20
ConstipationGastrointestinal disorders9/20
VomitingGastrointestinal disorders8/20
HeadacheNervous system disorders7/20
HypertensionVascular disorders6/20
MalaiseGeneral disorders6/20
Neutrophil count decreasedInvestigations6/20
White blood cell count decreasedInvestigations6/20

Baseline characteristics

Full Analysis Set (FAS) included all participants who received at least 1 dose of study drug and have measurable disease at Baseline.

Age, Continuous
Age, Continuous(years)Niraparib 300 mg
Mean62.4 ± 10.69
Sex: Female, Male
Sex: Female, Male(Participants)Niraparib 300 mg
Female20
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Niraparib 300 mg
American Indian or Alaska Native0
Asian20
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Niraparib 300 mg
Japan20
Time from First Diagnosis to First Dose
Time from First Diagnosis to First Dose(years)Niraparib 300 mg
Median4.71 (2.5 to 16.2)
Primary Tumor Site
Primary Tumor Site(Participants)Niraparib 300 mg
Ovarian13
Primary Peritoneal5
Fallopian Tube2
Cancer Stage (FIGO) at Time of Initial Diagnosis
Cancer Stage (FIGO) at Time of Initial Diagnosis(Participants)Niraparib 300 mg
IA1
IC1
IIB1
IIC1
IIIA1
IIIC12
IV3
Height
Height(centimeters (cm))Niraparib 300 mg
Mean155.9 ± 5.78

23 further baseline measures are reported on the registry.

08

Study locations

33 sites
  • Aichi Cancer Center Hospital
    Nagoya, Aichi, Japan
  • Hirosaki University Hospital
    Hirosaki, Aomori, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba, Japan
  • The Jikei University Kashiwa Hospital
    Kashiwa, Chiba, Japan
  • Shikoku Cancer Center
    Matsuyama, Ehime, Japan
  • Ehime University Hospital
    Toon, Ehime, Japan
  • Kurume University Hospital
    Kurume, Fukuoka, Japan
  • Kure Medical Center and Chugoku Cancer Center
    Kure, Hiroshima, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido, Japan
  • Hyogo Cancer Center
    Akashi, Hyogo, Japan
  • Kansai Rosai Hospital
    Amagasaki, Hyogo, Japan
  • Iwate Medical University Hospital
    Morioka, Iwate, Japan
  • Tokai University Hospital
    Isehara, Kanagawa, Japan
  • Nippon Medical School Musashi Kosugi Hospital
    Kawasaki, Kanagawa, Japan
  • Mie University Hospital
    Tsu, Mie, Japan
  • Tohoku University Hospital
    Sendai, Miyagi, Japan
  • University of the Ryukyus Hospital
    Nakagami-gun, Okinawa, Japan
  • Kindai University Hospital
    Osakasayama, Osaka, Japan
  • Saitama Medical University International Medical Center
    Hidaka, Saitama, Japan
  • Shizuoka Cancer Center
    Nagaizumi-cho, Shizuoka, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo, Japan
  • Cancer Institute Hospital
    Koto-ku, Tokyo, Japan
  • The Jikei University Hospital
    Minato-ku, Tokyo, Japan
  • Toho University Omori Medical Center
    Ota-ku, Tokyo, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo, Japan
  • Chiba Cancer Center
    Chiba, Japan
  • Chiba University Hospital
    Chiba, Japan
  • Gifu University Hospital
    Gifu, Japan
  • Kagoshima City Hospital
    Kagoshima, Japan
  • Kyoto University Hospital
    Kyoto, Japan
  • Nagasaki University Hospital
    Nagasaki, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, Japan
09

References and documents

Publications

  • Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T. Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10. PubMed 33327047 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Dec 2022, 48 months.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 48 months is above that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Nov 30, 2018
StartActual
Dec 26, 2018
Primary completionActual
Dec 28, 2022
CompletionActual
Dec 28, 2022
Results first posted
Aug 11, 2020
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03759600
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 30, 2018
Start date
Dec 26, 2018
Primary completion
Dec 28, 2022
Completion
Dec 28, 2022
Results posted
Aug 11, 2020
Last update
Jul 16, 2024

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion